{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import threading\n",
    "import time\n",
    "import openai\n",
    "from threading import Lock\n",
    "from langchain_community.embeddings import OpenAIEmbeddings\n",
    "# from langchain_openai import OpenAIEmbeddings\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "import json\n",
    "from langchain_community.vectorstores import Chroma\n",
    "import pandas as pd\n",
    "import sys\n",
    "import ast"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv(\"FinalCTTrialsDF_Full_w_ContactInfo_LocList_testing.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 15 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \n",
       "0     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...  \n",
       "...                                                 ...  \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...  \n",
       "\n",
       "[3836 rows x 15 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugs_biomarkers_template=f'''\n",
    "    Please extract all the names of the drugs and biomarkers from the information provided\n",
    "    ---BEGIN FORMAT TEMPLATE---\n",
    "{{\"DRUGS\":\"list of name of the drugs\"\n",
    "\"BIOMARKERS\":\"list of name of the biomarker\"}}\n",
    "---END FORMAT TEMPLATE---\n",
    "Give the output of the format template in json format\n",
    "    '''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_drugs_biomarkers(user_prompt):\n",
    "        \n",
    "        system_prompt=f'''\n",
    "    Please extract all the names of the drugs and biomarkers from the information provided\n",
    "    ---BEGIN FORMAT TEMPLATE---\n",
    "{{\"DRUGS\":\"list of name of the drugs\",\"BIOMARKERS\":\"list of name of the biomarker\"}}\n",
    "---END FORMAT TEMPLATE---\n",
    "Give the output of the format template in json format\n",
    "    '''\n",
    "        \n",
    "        \n",
    "        \n",
    "        \n",
    "        response = openai.chat.completions.create(\n",
    "            model='gpt-4-0125-preview',\n",
    "            temperature=0,\n",
    "            messages=[\n",
    "                {\"role\":\"system\", \"content\":system_prompt},\n",
    "                {\"role\":\"user\", \"content\":str(user_prompt)},\n",
    "            ],\n",
    "            max_tokens = 1024,\n",
    "            response_format={ \"type\": \"json_object\" }\n",
    "            \n",
    "        )\n",
    "        res = response.choices[0].message.content\n",
    "        return res\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"drugs & biomarker\"]=df[\"INTERVENTIONS\"].apply(get_drugs_biomarkers)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>drugs &amp; biomarker</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 16 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                                      drugs & biomarker  \n",
       "0     {\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...  \n",
       "1     {\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...  \n",
       "2                {\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}  \n",
       "3                          {\"DRUGS\":[],\"BIOMARKERS\":[]}  \n",
       "4     {\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...  \n",
       "...                                                 ...  \n",
       "3831                {\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}  \n",
       "3832  {\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...  \n",
       "3833  {\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...  \n",
       "3834                 {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}  \n",
       "3835  {\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...  \n",
       "\n",
       "[3836 rows x 16 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('finalcttrial.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       {\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...\n",
       "1       {\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...\n",
       "2                  {\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}\n",
       "3                            {\"DRUGS\":[],\"BIOMARKERS\":[]}\n",
       "4       {\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...\n",
       "                              ...                        \n",
       "3831                  {\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}\n",
       "3832    {\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...\n",
       "3833    {\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...\n",
       "3834                   {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}\n",
       "3835    {\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...\n",
       "Name: drugs & biomarker, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"drugs & biomarker\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "def parse_dict(text):\n",
    "    try:\n",
    "        return ast.literal_eval(text)\n",
    "    except ValueError:\n",
    "        return {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"DRUGS\"] = df[\"drugs & biomarker\"].apply(lambda x: parse_dict(x).get(\"DRUGS\", []))\n",
    "df[\"BIOMARKERS\"] = df[\"drugs & biomarker\"].apply(lambda x: parse_dict(x).get(\"BIOMARKERS\", []))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       [JS004, JS001, docetaxel, pemetrexed, carbopla...\n",
       "1                                                  [IL-2]\n",
       "2                                              [APG-2449]\n",
       "3                                                      []\n",
       "4                         [Pembrolizumab, Bojungikgitang]\n",
       "                              ...                        \n",
       "3831                                                   []\n",
       "3832    [Pegylated Liposomal Doxorubicin, Weekly Pacli...\n",
       "3833                                                   []\n",
       "3834                                                   []\n",
       "3835                              [sulforaphane, placebo]\n",
       "Name: DRUGS, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"DRUGS\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"DRUGS\"] = df[\"DRUGS\"].apply(lambda x: ', '.join(x) if isinstance(x, list) else '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       JS004, JS001, docetaxel, pemetrexed, carboplat...\n",
       "1                                                    IL-2\n",
       "2                                                APG-2449\n",
       "3                                                        \n",
       "4                           Pembrolizumab, Bojungikgitang\n",
       "                              ...                        \n",
       "3831                                                     \n",
       "3832    Pegylated Liposomal Doxorubicin, Weekly Paclit...\n",
       "3833                                                     \n",
       "3834                                                     \n",
       "3835                                sulforaphane, placebo\n",
       "Name: DRUGS, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"DRUGS\"] "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "df[\"BIOMARKERS\"] = df[\"BIOMARKERS\"].apply(lambda x: ', '.join(x) if isinstance(x, list) else '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>drugs &amp; biomarker</th>\n",
       "      <th>DRUGS</th>\n",
       "      <th>BIOMARKERS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...</td>\n",
       "      <td>JS004, JS001, docetaxel, pemetrexed, carboplat...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...</td>\n",
       "      <td>IL-2</td>\n",
       "      <td>CD39, CD103, PD-1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}</td>\n",
       "      <td>APG-2449</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...</td>\n",
       "      <td>Pembrolizumab, Bojungikgitang</td>\n",
       "      <td>PD-1 receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>3831</td>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}</td>\n",
       "      <td></td>\n",
       "      <td>CAPS3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>3832</td>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...</td>\n",
       "      <td>Pegylated Liposomal Doxorubicin, Weekly Paclit...</td>\n",
       "      <td>PD-1, PARP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>3833</td>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...</td>\n",
       "      <td></td>\n",
       "      <td>MRI DWIBS, DWIBS-MRI ADC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>3834</td>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}</td>\n",
       "      <td></td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>3835</td>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...</td>\n",
       "      <td>sulforaphane, placebo</td>\n",
       "      <td>sulforaphane levels</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Unnamed: 0   NCT_NUMBER  \\\n",
       "0              0  NCT05664971   \n",
       "1              1  NCT05902520   \n",
       "2              2  NCT03917043   \n",
       "3              3  NCT05674422   \n",
       "4              4  NCT06249854   \n",
       "...          ...          ...   \n",
       "3831        3831  NCT05006131   \n",
       "3832        3832  NCT04679064   \n",
       "3833        3833  NCT04491864   \n",
       "3834        3834  NCT05905939   \n",
       "3835        3835  NCT03934905   \n",
       "\n",
       "                                            STUDY_TITLE  \\\n",
       "0     JS004 Combined With Toripalimab and With Stand...   \n",
       "1     Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2       APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     Efficacy and Safety of Combination Therapy Wit...   \n",
       "...                                                 ...   \n",
       "3831  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                                      drugs & biomarker  \\\n",
       "0     {\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...   \n",
       "1     {\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...   \n",
       "2                {\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}   \n",
       "3                          {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "4     {\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...   \n",
       "...                                                 ...   \n",
       "3831                {\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}   \n",
       "3832  {\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...   \n",
       "3833  {\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...   \n",
       "3834                 {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}   \n",
       "3835  {\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...   \n",
       "\n",
       "                                                  DRUGS  \\\n",
       "0     JS004, JS001, docetaxel, pemetrexed, carboplat...   \n",
       "1                                                  IL-2   \n",
       "2                                              APG-2449   \n",
       "3                                                         \n",
       "4                         Pembrolizumab, Bojungikgitang   \n",
       "...                                                 ...   \n",
       "3831                                                      \n",
       "3832  Pegylated Liposomal Doxorubicin, Weekly Paclit...   \n",
       "3833                                                      \n",
       "3834                                                      \n",
       "3835                              sulforaphane, placebo   \n",
       "\n",
       "                    BIOMARKERS  \n",
       "0                               \n",
       "1            CD39, CD103, PD-1  \n",
       "2                               \n",
       "3                               \n",
       "4                PD-1 receptor  \n",
       "...                        ...  \n",
       "3831                     CAPS3  \n",
       "3832                PD-1, PARP  \n",
       "3833  MRI DWIBS, DWIBS-MRI ADC  \n",
       "3834                      HER2  \n",
       "3835       sulforaphane levels  \n",
       "\n",
       "[3836 rows x 18 columns]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('Unnamed: 0',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>LOCATIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>drugs &amp; biomarker</th>\n",
       "      <th>DRUGS</th>\n",
       "      <th>BIOMARKERS</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05664971</td>\n",
       "      <td>JS004 Combined With Toripalimab and With Stand...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05664971</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Shanghai Chest Hospita...</td>\n",
       "      <td>February 9, 2023</td>\n",
       "      <td>November 17, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants include males or females...</td>\n",
       "      <td>The primary outcomes include the incidence of ...</td>\n",
       "      <td>Secondary outcomes encompass the duration of r...</td>\n",
       "      <td>The study involves multiple cohorts receiving ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...</td>\n",
       "      <td>JS004, JS001, docetaxel, pemetrexed, carboplat...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05902520</td>\n",
       "      <td>Adoptive Cell Therapy Using Cancer Specific CD...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05902520</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>HNSCC, Melanoma, Gynecologic Cancer, Colorecta...</td>\n",
       "      <td>[{'Location Facility': 'Providence Portland Me...</td>\n",
       "      <td>June 19, 2023</td>\n",
       "      <td>May 19, 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults over 18 with histo...</td>\n",
       "      <td>The primary outcome is to assess the safety of...</td>\n",
       "      <td>Secondary outcomes include evaluating the effi...</td>\n",
       "      <td>The study involves two experimental arms. Both...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...</td>\n",
       "      <td>IL-2</td>\n",
       "      <td>CD39, CD103, PD-1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03917043</td>\n",
       "      <td>APG-2449 in Patients With Advanced Solid Tumors</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03917043</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Solid Cancer, Non Small Cell Lung Can...</td>\n",
       "      <td>[{'Location Facility': 'Beijing Cancer Hospita...</td>\n",
       "      <td>May 27, 2019</td>\n",
       "      <td>February 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with advanced tu...</td>\n",
       "      <td>The primary outcomes are to determine the maxi...</td>\n",
       "      <td>Secondary outcomes include measuring the maxim...</td>\n",
       "      <td>The intervention involves administering APG-24...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}</td>\n",
       "      <td>APG-2449</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05674422</td>\n",
       "      <td>GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05674422</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Patients With Locally Advanced Rectal Cancer</td>\n",
       "      <td>[{'Location Facility': 'Hospital Germans Trias...</td>\n",
       "      <td>May 26, 2023</td>\n",
       "      <td>July 2026</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are legally capable indi...</td>\n",
       "      <td>The primary outcome measure is the detection o...</td>\n",
       "      <td>Secondary outcomes include the classification ...</td>\n",
       "      <td>The intervention involves total neoadjuvant th...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[]}</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT06249854</td>\n",
       "      <td>Efficacy and Safety of Combination Therapy Wit...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06249854</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>[{'Location Facility': 'Korea University Ansan...</td>\n",
       "      <td>February 8, 2024</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>19 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults aged 19 or older w...</td>\n",
       "      <td>The primary outcome measure is Progression-Fre...</td>\n",
       "      <td>Secondary outcomes include Disease Control Rat...</td>\n",
       "      <td>The study involves two groups: one receiving P...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...</td>\n",
       "      <td>Pembrolizumab, Bojungikgitang</td>\n",
       "      <td>PD-1 receptor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3831</th>\n",
       "      <td>NCT05006131</td>\n",
       "      <td>Pancreatic Cancer Screening for At-risk Indivi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05006131</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer, Adult</td>\n",
       "      <td>[{'Location Facility': 'Beth Israel Deaconess ...</td>\n",
       "      <td>July 10, 2020</td>\n",
       "      <td>July 10, 2026</td>\n",
       "      <td>18 Years|90 Years|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals indicated for...</td>\n",
       "      <td>The primary outcome is the proportion of scree...</td>\n",
       "      <td>Secondary outcomes include the proportion of s...</td>\n",
       "      <td>The intervention involves screening for pancre...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}</td>\n",
       "      <td></td>\n",
       "      <td>CAPS3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3832</th>\n",
       "      <td>NCT04679064</td>\n",
       "      <td>Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04679064</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[{'Location Facility': 'Azienda Ospedaliera Sp...</td>\n",
       "      <td>December 1, 2020</td>\n",
       "      <td>January 1, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes recurrent ovarian, Fallop...</td>\n",
       "      <td>The primary outcome measure is overall surviva...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Interventions include a choice of standard che...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...</td>\n",
       "      <td>Pegylated Liposomal Doxorubicin, Weekly Paclit...</td>\n",
       "      <td>PD-1, PARP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3833</th>\n",
       "      <td>NCT04491864</td>\n",
       "      <td>DWIBS-MRI: An Adjunct to the Traditional Diagn...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04491864</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Baylor Scott &amp; White R...</td>\n",
       "      <td>March 11, 2019</td>\n",
       "      <td>March 11, 2024</td>\n",
       "      <td>30 Years||Adult|Older Adult</td>\n",
       "      <td>Eligible participants are genetic females over...</td>\n",
       "      <td>The study aims to assess the accuracy of MRI D...</td>\n",
       "      <td>No secondary outcomes were provided.</td>\n",
       "      <td>The document does not specify interventions, f...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...</td>\n",
       "      <td></td>\n",
       "      <td>MRI DWIBS, DWIBS-MRI ADC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3834</th>\n",
       "      <td>NCT05905939</td>\n",
       "      <td>HER2(Human Epidermal Growth Factor Receptor 2)...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05905939</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>[{'Location Facility': 'Research Site', 'Locat...</td>\n",
       "      <td>May 31, 2023</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>||Child|Adult|Older Adult</td>\n",
       "      <td>Eligibility includes patients with HER2-positi...</td>\n",
       "      <td>The primary outcomes aim to describe the clini...</td>\n",
       "      <td>Secondary outcomes focus on describing diagnos...</td>\n",
       "      <td>The study does not specify interventions, as i...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}</td>\n",
       "      <td></td>\n",
       "      <td>HER2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3835</th>\n",
       "      <td>NCT03934905</td>\n",
       "      <td>Protective Effects of the Nutritional Suppleme...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03934905</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Anthracycline Related Cardiotoxicity in Breast...</td>\n",
       "      <td>[{'Location Facility': 'Texas Tech University ...</td>\n",
       "      <td>June 1, 2022</td>\n",
       "      <td>June 1, 2026</td>\n",
       "      <td>18 Years|89 Years|Adult|Older Adult</td>\n",
       "      <td>Participants aged 18 to 89, without prior diag...</td>\n",
       "      <td>The primary outcome is the change in cardiac f...</td>\n",
       "      <td>Secondary outcomes include monitoring troponin...</td>\n",
       "      <td>Participants will receive either sulforaphane ...</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>{\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...</td>\n",
       "      <td>sulforaphane, placebo</td>\n",
       "      <td>sulforaphane levels</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3836 rows × 17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       NCT_NUMBER                                        STUDY_TITLE  \\\n",
       "0     NCT05664971  JS004 Combined With Toripalimab and With Stand...   \n",
       "1     NCT05902520  Adoptive Cell Therapy Using Cancer Specific CD...   \n",
       "2     NCT03917043    APG-2449 in Patients With Advanced Solid Tumors   \n",
       "3     NCT05674422  GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...   \n",
       "4     NCT06249854  Efficacy and Safety of Combination Therapy Wit...   \n",
       "...           ...                                                ...   \n",
       "3831  NCT05006131  Pancreatic Cancer Screening for At-risk Indivi...   \n",
       "3832  NCT04679064  Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...   \n",
       "3833  NCT04491864  DWIBS-MRI: An Adjunct to the Traditional Diagn...   \n",
       "3834  NCT05905939  HER2(Human Epidermal Growth Factor Receptor 2)...   \n",
       "3835  NCT03934905  Protective Effects of the Nutritional Suppleme...   \n",
       "\n",
       "                                             STUDY_URL STUDY_STATUS  \\\n",
       "0     https://www.clinicaltrials.gov/study/NCT05664971   Recruiting   \n",
       "1     https://www.clinicaltrials.gov/study/NCT05902520   Recruiting   \n",
       "2     https://www.clinicaltrials.gov/study/NCT03917043   Recruiting   \n",
       "3     https://www.clinicaltrials.gov/study/NCT05674422   Recruiting   \n",
       "4     https://www.clinicaltrials.gov/study/NCT06249854   Recruiting   \n",
       "...                                                ...          ...   \n",
       "3831  https://www.clinicaltrials.gov/study/NCT05006131   Recruiting   \n",
       "3832  https://www.clinicaltrials.gov/study/NCT04679064   Recruiting   \n",
       "3833  https://www.clinicaltrials.gov/study/NCT04491864   Recruiting   \n",
       "3834  https://www.clinicaltrials.gov/study/NCT05905939   Recruiting   \n",
       "3835  https://www.clinicaltrials.gov/study/NCT03934905   Recruiting   \n",
       "\n",
       "                                             CONDITIONS  \\\n",
       "0                                  Advanced Lung Cancer   \n",
       "1     HNSCC, Melanoma, Gynecologic Cancer, Colorecta...   \n",
       "2     Advanced Solid Cancer, Non Small Cell Lung Can...   \n",
       "3          Patients With Locally Advanced Rectal Cancer   \n",
       "4                            Non-small Cell Lung Cancer   \n",
       "...                                                 ...   \n",
       "3831                           Pancreatic Cancer, Adult   \n",
       "3832                                     Ovarian Cancer   \n",
       "3833                                      Breast Cancer   \n",
       "3834                                      Breast Cancer   \n",
       "3835  Anthracycline Related Cardiotoxicity in Breast...   \n",
       "\n",
       "                                              LOCATIONS        START_DATE  \\\n",
       "0     [{'Location Facility': 'Shanghai Chest Hospita...  February 9, 2023   \n",
       "1     [{'Location Facility': 'Providence Portland Me...     June 19, 2023   \n",
       "2     [{'Location Facility': 'Beijing Cancer Hospita...      May 27, 2019   \n",
       "3     [{'Location Facility': 'Hospital Germans Trias...      May 26, 2023   \n",
       "4     [{'Location Facility': 'Korea University Ansan...  February 8, 2024   \n",
       "...                                                 ...               ...   \n",
       "3831  [{'Location Facility': 'Beth Israel Deaconess ...     July 10, 2020   \n",
       "3832  [{'Location Facility': 'Azienda Ospedaliera Sp...  December 1, 2020   \n",
       "3833  [{'Location Facility': 'Baylor Scott & White R...    March 11, 2019   \n",
       "3834  [{'Location Facility': 'Research Site', 'Locat...      May 31, 2023   \n",
       "3835  [{'Location Facility': 'Texas Tech University ...      June 1, 2022   \n",
       "\n",
       "        COMPLETION_DATE                                  AGE  \\\n",
       "0     November 17, 2024          18 Years||Adult|Older Adult   \n",
       "1          May 19, 2026          18 Years||Adult|Older Adult   \n",
       "2         February 2025          18 Years||Adult|Older Adult   \n",
       "3             July 2026          18 Years||Adult|Older Adult   \n",
       "4     December 31, 2025          19 Years||Adult|Older Adult   \n",
       "...                 ...                                  ...   \n",
       "3831      July 10, 2026  18 Years|90 Years|Adult|Older Adult   \n",
       "3832    January 1, 2025          18 Years||Adult|Older Adult   \n",
       "3833     March 11, 2024          30 Years||Adult|Older Adult   \n",
       "3834       May 31, 2024            ||Child|Adult|Older Adult   \n",
       "3835       June 1, 2026  18 Years|89 Years|Adult|Older Adult   \n",
       "\n",
       "                                   ELIGIBILITY_CRITERIA  \\\n",
       "0     Eligible participants include males or females...   \n",
       "1     Eligibility includes adults over 18 with histo...   \n",
       "2     Eligibility includes patients with advanced tu...   \n",
       "3     Eligible participants are legally capable indi...   \n",
       "4     Eligibility includes adults aged 19 or older w...   \n",
       "...                                                 ...   \n",
       "3831  Eligibility includes individuals indicated for...   \n",
       "3832  Eligibility includes recurrent ovarian, Fallop...   \n",
       "3833  Eligible participants are genetic females over...   \n",
       "3834  Eligibility includes patients with HER2-positi...   \n",
       "3835  Participants aged 18 to 89, without prior diag...   \n",
       "\n",
       "                                       PRIMARY_OUTCOMES  \\\n",
       "0     The primary outcomes include the incidence of ...   \n",
       "1     The primary outcome is to assess the safety of...   \n",
       "2     The primary outcomes are to determine the maxi...   \n",
       "3     The primary outcome measure is the detection o...   \n",
       "4     The primary outcome measure is Progression-Fre...   \n",
       "...                                                 ...   \n",
       "3831  The primary outcome is the proportion of scree...   \n",
       "3832  The primary outcome measure is overall surviva...   \n",
       "3833  The study aims to assess the accuracy of MRI D...   \n",
       "3834  The primary outcomes aim to describe the clini...   \n",
       "3835  The primary outcome is the change in cardiac f...   \n",
       "\n",
       "                                     SECONDARY_OUTCOMES  \\\n",
       "0     Secondary outcomes encompass the duration of r...   \n",
       "1     Secondary outcomes include evaluating the effi...   \n",
       "2     Secondary outcomes include measuring the maxim...   \n",
       "3     Secondary outcomes include the classification ...   \n",
       "4     Secondary outcomes include Disease Control Rat...   \n",
       "...                                                 ...   \n",
       "3831  Secondary outcomes include the proportion of s...   \n",
       "3832  Secondary outcomes include progression-free su...   \n",
       "3833               No secondary outcomes were provided.   \n",
       "3834  Secondary outcomes focus on describing diagnos...   \n",
       "3835  Secondary outcomes include monitoring troponin...   \n",
       "\n",
       "                                          INTERVENTIONS  \\\n",
       "0     The study involves multiple cohorts receiving ...   \n",
       "1     The study involves two experimental arms. Both...   \n",
       "2     The intervention involves administering APG-24...   \n",
       "3     The intervention involves total neoadjuvant th...   \n",
       "4     The study involves two groups: one receiving P...   \n",
       "...                                                 ...   \n",
       "3831  The intervention involves screening for pancre...   \n",
       "3832  Interventions include a choice of standard che...   \n",
       "3833  The document does not specify interventions, f...   \n",
       "3834  The study does not specify interventions, as i...   \n",
       "3835  Participants will receive either sulforaphane ...   \n",
       "\n",
       "                                       POINT_OF_CONTACT  \\\n",
       "0     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "1     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "2     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "4     {'Name': None, 'Organization': None, 'Email': ...   \n",
       "...                                                 ...   \n",
       "3831  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3832  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3833  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3834  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "3835  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "                                      drugs & biomarker  \\\n",
       "0     {\"DRUGS\":[\"JS004\",\"JS001\",\"docetaxel\",\"pemetre...   \n",
       "1     {\\n\"DRUGS\":[\"IL-2\"],\\n\"BIOMARKERS\":[\"CD39\", \"C...   \n",
       "2                {\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[]}   \n",
       "3                          {\"DRUGS\":[],\"BIOMARKERS\":[]}   \n",
       "4     {\\n\"DRUGS\":[\"Pembrolizumab\", \"Bojungikgitang\"]...   \n",
       "...                                                 ...   \n",
       "3831                {\"DRUGS\":[],\"BIOMARKERS\":[\"CAPS3\"]}   \n",
       "3832  {\"DRUGS\":[\"Pegylated Liposomal Doxorubicin\", \"...   \n",
       "3833  {\\n\"DRUGS\":[],\\n\"BIOMARKERS\":[\"MRI DWIBS\", \"DW...   \n",
       "3834                 {\"DRUGS\":[],\"BIOMARKERS\":[\"HER2\"]}   \n",
       "3835  {\"DRUGS\":[\"sulforaphane\",\"placebo\"],\"BIOMARKER...   \n",
       "\n",
       "                                                  DRUGS  \\\n",
       "0     JS004, JS001, docetaxel, pemetrexed, carboplat...   \n",
       "1                                                  IL-2   \n",
       "2                                              APG-2449   \n",
       "3                                                         \n",
       "4                         Pembrolizumab, Bojungikgitang   \n",
       "...                                                 ...   \n",
       "3831                                                      \n",
       "3832  Pegylated Liposomal Doxorubicin, Weekly Paclit...   \n",
       "3833                                                      \n",
       "3834                                                      \n",
       "3835                              sulforaphane, placebo   \n",
       "\n",
       "                    BIOMARKERS  \n",
       "0                               \n",
       "1            CD39, CD103, PD-1  \n",
       "2                               \n",
       "3                               \n",
       "4                PD-1 receptor  \n",
       "...                        ...  \n",
       "3831                     CAPS3  \n",
       "3832                PD-1, PARP  \n",
       "3833  MRI DWIBS, DWIBS-MRI ADC  \n",
       "3834                      HER2  \n",
       "3835       sulforaphane levels  \n",
       "\n",
       "[3836 rows x 17 columns]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('finalcttrial.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Unnamed: 0', 'NCT_NUMBER', 'STUDY_TITLE', 'STUDY_URL', 'STUDY_STATUS',\n",
       "       'CONDITIONS', 'LOCATIONS', 'START_DATE', 'COMPLETION_DATE', 'AGE',\n",
       "       'ELIGIBILITY_CRITERIA', 'PRIMARY_OUTCOMES', 'SECONDARY_OUTCOMES',\n",
       "       'INTERVENTIONS', 'POINT_OF_CONTACT', 'drugs & biomarker', 'DRUGS',\n",
       "       'BIOMARKERS'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['CONTENT'] = df[['STUDY_TITLE', 'ELIGIBILITY_CRITERIA','PRIMARY_OUTCOMES','SECONDARY_OUTCOMES','INTERVENTIONS']].apply(lambda x: ' '.join(x), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       JS004 Combined With Toripalimab and With Stand...\n",
       "1       Adoptive Cell Therapy Using Cancer Specific CD...\n",
       "2       APG-2449 in Patients With Advanced Solid Tumor...\n",
       "3       GEMCAD-REVEAL STUDY - Circulating Tumor DNA as...\n",
       "4       Efficacy and Safety of Combination Therapy Wit...\n",
       "                              ...                        \n",
       "3831    Pancreatic Cancer Screening for At-risk Indivi...\n",
       "3832    Trial on NIraparib-TSR-042 (Dostarlimab) vs Ph...\n",
       "3833    DWIBS-MRI: An Adjunct to the Traditional Diagn...\n",
       "3834    HER2(Human Epidermal Growth Factor Receptor 2)...\n",
       "3835    Protective Effects of the Nutritional Suppleme...\n",
       "Name: CONTENT, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['CONTENT']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    {\"DRUGS\":[\"JS004\",\"Toripalimab\",\"Standard Chem...\n",
       "1    {\"DRUGS\":[\"IL-2\",\"siRNA PD-1\"],\"BIOMARKERS\":[\"...\n",
       "2    {\"DRUGS\":[\"APG-2449\"],\"BIOMARKERS\":[\"ALK\",\"ROS...\n",
       "3    {\"DRUGS\":[],\"BIOMARKERS\":[\"circulating tumor D...\n",
       "4    {\"DRUGS\":[\"Bojungikki-tang\",\"Pembrolizumab\"],\"...\n",
       "Name: CONTENT, dtype: object"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"CONTENT\"][0:5].apply(get_drugs_biomarkers)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0       Recruiting\n",
       "1       Recruiting\n",
       "2       Recruiting\n",
       "3       Recruiting\n",
       "4       Recruiting\n",
       "           ...    \n",
       "3831    Recruiting\n",
       "3832    Recruiting\n",
       "3833    Recruiting\n",
       "3834    Recruiting\n",
       "3835    Recruiting\n",
       "Name: STUDY_STATUS, Length: 3836, dtype: object"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
